RxDoctor Payments Data

Morgan Hayes McAlvin, APRN

Family · Atlanta, GANPI 1972175578

Payments from drug & device makers

$3,936in general payments, 2019–2025

Across 182 payments — averaging $21.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$562
  • Otsuka America Pharmaceutical, Inc.$472
  • Calliditas Therapeutics US Inc.$434
  • Amgen$381
  • Aurinia Pharma U.S., Inc.$285
  • Bayer$264
  • plus $2K from 18 others

What the payments were for

  • Food & beverage$3,91499%
  • Education$221%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,936 in reported general payments places this provider in the 90th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$106,061
Medicare patients
565
Services billed
2,506

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol12$12,284
Nifedipine ErNifedipine70$3,129
Potassium Chloride38$1,330
Torsemide52$1,231
Carvedilol96$995
Olmesartan Medoxomil71$757
Doxazosin Mesylate48$746
Valsartan24$530
Spironolactone22$512
Hydralazine Hcl36$484
Amlodipine Besylate88$445
Calcitriol21$432
Furosemide117$416
Allopurinol49$378
Lisinopril41$303

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$562$12,28412 claims
ANI Pharmaceuticals, Inc.Valsartan$37$53024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,258 family providers in Georgia.

Other family in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →